Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

Benzinga Newsdesk www.benzinga.com Positive 56.9%

Neg 0% Neu 0% Pos 56.9%

Rodman & Renshaw initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy rating and announces Price Target of $11.